RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Larimar Therapeutics ROA 2024

Larimar Therapeutics ROA

-0.39

Larimar Therapeutics Dividend yield

Ticker

LRMR

ISIN

US5171251003

WKN

A2P5PP

In 2024, Larimar Therapeutics's return on assets (ROA) was -0.39, a 37.68% increase from the -0.28 ROA in the previous year.

Larimar Therapeutics Aktienanalyse

What does Larimar Therapeutics do?

Larimar Therapeutics Inc is a US biotechnology company focused on developing therapies for rare genetic diseases. It was founded in 2018 and is based in Philadelphia, Pennsylvania. The company's mission is to accelerate the development of therapies for patients with rare genetic diseases through collaboration with academic researchers, patient organizations, and industry partners. They are active in various therapeutic areas, including neurological diseases, genetic metabolic disorders, and rare inherited diseases, with a diverse portfolio of drug candidates in different stages of clinical development. Their main focus is on developing therapies for Friedreich's ataxia, a rare neurological disease, and other neurologic disorders. They are also working on therapies for rare genetic metabolic disorders such as PKU and HFI. Larimar Therapeutics aims to improve the quality of life for patients with rare inherited diseases and adopts an innovative and patient-centered approach to their drug development. Collaborations and partnerships are integral to their strategy in order to make faster progress in the treatment of these often severe diseases. Larimar Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Larimar Therapeutics's Return on Assets (ROA)

Larimar Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Larimar Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Larimar Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Larimar Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Larimar Therapeutics Stock

What is the Return on Assets (ROA) of Larimar Therapeutics this year?

The Return on Assets (ROA) of Larimar Therapeutics is -0.39 undefined this year.

What was the ROA of Larimar Therapeutics compared to the previous year?

The ROA of Larimar Therapeutics has increased by 37.68% compared to the previous year.

What consequences do high ROA have for investors of Larimar Therapeutics?

A high ROA is advantageous for investors of Larimar Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Larimar Therapeutics?

A low ROA can be unfavorable for investors of Larimar Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Larimar Therapeutics affect the company?

An increase in ROA of Larimar Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Larimar Therapeutics impact the company?

A reduction in the ROA of Larimar Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Larimar Therapeutics?

Some factors that can influence the ROA of Larimar Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Larimar Therapeutics important for investors?

The ROA of Larimar Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Larimar Therapeutics take to improve ROA?

To improve ROA, Larimar Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Larimar Therapeutics pay?

Over the past 12 months, Larimar Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Larimar Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Larimar Therapeutics?

The current dividend yield of Larimar Therapeutics is .

When does Larimar Therapeutics pay dividends?

Larimar Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Larimar Therapeutics?

Larimar Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Larimar Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Larimar Therapeutics located?

Larimar Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Larimar Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Larimar Therapeutics from 4/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/28/2024.

When did Larimar Therapeutics pay the last dividend?

The last dividend was paid out on 4/28/2024.

What was the dividend of Larimar Therapeutics in the year 2023?

In the year 2023, Larimar Therapeutics distributed 0 USD as dividends.

In which currency does Larimar Therapeutics pay out the dividend?

The dividends of Larimar Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Larimar Therapeutics

Our stock analysis for Larimar Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Larimar Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.